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Until discovery of antibiotics, studies on che-
mical composition of fungi had not been very popu-
lar. People preferred to look for medicinal compo-
unds in plants, while fungi remained distrusted and
wrapped in superstitious fear. In ancient times, indi-
genous people of North and South America made
use of hallucinogenic properties of fungi of the Psi-
locybe, Stropharia genera. Cultures of Asian coun-
tries, particularly of China and Japan, preserved be-
lief that fungi had rejuvenating, regenerating and to-
nic effects in humans. They even cultivated such
fungal species as Cordyceps sinensis and Hericium
erinaceum. Folk medicine of European countries al-
so utilized fungi as a source of medicinal substances
used in such diseases as tumors, hepatitis, asthma,
hemorrhoids. Of our indigenous species, Fomitopsis
officinalis (= Laricifomes off.), Inonotus bliquus and
Piptoporus betulinus deserve to be mentioned. 
Discovery of penicillin confirmed in the scien-
tific way the fact that fungi can be a very rich sour-
ce of natural medicinal substances, including life-sa-
ving drugs. This greatly widened research horizons,
raised their many-sided significance and joined ef-
forts of researchers working in different and appa-
rently unconnected fields like mycology, chemistry,
pharmacy and medicine.
The increased interest in chemical composition
of fungi in the search for biologically active metabo-
lites led to discovery of substances endowed with
multifarious actions. However, as plant research still
prevails, higher fungi are less valued and considered
to be of minor significance. Lesser interest in fungi
results mostly from difficulties in collection of ma-
terial growing in a natural environment i.e., exclusi-
vely fruit bodies, and from troubles with proper sys-
tematic identification of fungi. These problems faci-
litated efforts aimed to obtain mycelial cultures of
fungi. Success in those fields has made the last three
decades, the period of the most intensive studies of
substances isolated from fungi. 
Among an array of substances of fungal origin,
polysaccharides have been a focus of the greatest in-
terest of biochemistry and medicine, due to their an-
titumor and immunomodulating properties. The ear-
liest report of antitumor activity of polysaccharides
was published in 1943, when a compound isolated
from bacteria Serratia marcescens was shown to po-
ssess such activity (1). This polysaccharide induced
cytostatic effect on Sarcoma-37 cells in mice after
its intraperitoneal administration. However, clinical
tests were not continued because of severe side ef-
fects and toxicity of this compound. The interest in
cytotoxic substances included in fungi began in the
early 40s of the 20th century when a strongly immu-
nostimulating polysaccharide complex was isolated
from Saccharomyces cerevisiae cell wall. It was de-
monstrated to induce macrophage activation and to
stimulate reticuloendothelial system (2). 
Long-term research carried out by the Chair
and Department of Pharmaceutical Botany Colle-
gium Medicum, Jagiellonian University, made
a fundamental contribution to searching for biologi-
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cally active substances that could be isolated from
mushrooms and their mycelial cultures (3-6).
In 1992, there were isolated mitostatically acti-
ve polysaccharides from T-411 strain of Saccharo-
myces cerevisiae Meyen (7). Other biologically acti-
ve polysaccharides obtained from Saccharomyces ce-
revisiae were studied in vasoprotective aspects sho-
wing an inhibition of filtration of microvessels in the
course of inflammatory pleutal effusion in rats (8).
Japanese researchers are given the greatest cre-
dit for isolating and evaluating antitumor activity of
fungal polysaccharides. It is reflected in a number of
papers in this field as well as in the introduction of
preparations of fungal origin in the health care (9,10).
Chemical structure of fungal polysaccharides
Fungal polysaccharides include mostly glu-
cans, mannans and galactans. Their molecular
weights are high ranging from 100 000 to 1 000 000 Da
(10). Biological activity is characteristic of β-glu-
cans in contrast to α-glucans which are rarely acti-
ve. Activity is determined by their chemical structu-
re, particularly by the type of glycoside bond (α or
β) and spatial structure of a polysaccharide molecu-
le. Polysaccharides with linear structure and witho-
ut long side chains show the highest activity, which
is connected with their better solubility and thereby
easier assimilability by the human body. Most often
β(1→3) bonds occur in the main chain while bran-
ches are formed by β(1→6) bonds. 
Mechanism of action of polysaccharides from
fungi
Mechanism of antitumor action of polysaccha-
rides consists in the stimulation of certain compo-
nents of the immune system, mainly T and B-lym-
phocytes, macrophages, and induction of interleukin
release by NK cells (10,11).
Since β-glucans did not show any cytotoxic or
cytostatic effects on tumor cells in in vivo tests, it
has been assumed that these compounds can act in-
directly by activation of the immune system, but are
unable to destroy directly tumor cells. Immunosti-
mulating action involves activation of natural
nonñspecific immunity (12). At present, such drugs
are most frequently used in combination with other
methods of therapy like radiotherapy or chemothera-
py after surgical removal of primary tumor. These
drugs were shown to prolong patientsí survival, in-
hibiting cancer development and improving general
condition of a patient. Polysaccharides are most
often administered parenterally, sometimes orally,
when the presence of peptide fragment allows for
such route. Method of administration of these com-
pounds, resulting mostly from their chemical struc-
ture is not burdensome to patients, which is the un-
doubted advantage of these compounds. Importan-
tly, these compounds are usually non-toxic and side
effects during treatment are rarely observed, most
often only local slight irritation can be noted on the
injection site. Small increase in body temperature
and vomiting occur sporadically, but the most frequ-
ently used intramuscular injections up to seven ti-
mes a week at a daily dose between 5-50 mg are
well-tolerated by patients. Proven positive therapeu-
tic effect without burdensome side effects is an un-
deniable advantage of these compounds (11-13).
Detailed mechanism of antitumor activity of indivi-
dual polysaccharides is described below.
The most important fungal polysaccharides used
in antitumor therapy
Therapeutically important polysaccharides ha-
ve been found as well in microscopic as in higher
fungi. These secondary metabolites have been isola-
ted both from fruiting bodies and from mycelial cul-
tures. Apart from their antitumor properties, these
compounds can also show other biological actions
e.g. antiñinflammatory, antibacterial, antiviral, anti-
parasitic, hypotensive, hypoglycemic and vasopro-
tective (10-12). Of many known pharmacologically
active fungal polysaccharides, lentinan and krestin
(so-called PSK) are used in clinical practice.
Lentinan was isolated from arboreal fungus
Lentinus edodes (shi-take). In terms of chemical
structure, it is β(1→3) glucan with branches at
β(1→6) bond, having molecular weight of 500 kDa
and structure of dextrorotary helix (14). This sub-
stance is considered to be the most active among
known polysaccharides endowed with antitumor po-
tential. It prevents neoplastic transformation caused
by chemical carcinogens and viruses, and inhibits
development of allogenic and some syngenic tumors
(15). This polysaccharide is most often used in the
Figure 1. Structure of tylopilan
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treatment of solid tumors of the stomach, large inte-
stine, breast, lungs and malignant leukemia. Proba-
ble mechanism of its action consists in stimulation
of T lymphocytes, induction of interleukin 1 and 3
and nitric oxide production by the immune cells,
elevation of CSF (colony stimulating factor) and
acute phase proteins levels, and direct and indirect
(through T lymphocytes) effect on macrophages
(15). It is used in combination with chemo- and ra-
diotherapy. It is important that lentinan has slight si-
de effects: local irritation after injection and spora-
dic fever and vomiting, but usually is well tolerated
by patients (16). Shi-take mushroom is native to Ja-
pan, China and other Asian countries and it usually
grows on fallen broadleaf trees.
The second most frequently used antitumor po-
lysaccharide, krestin (PSK), is obtained from myce-
lium of an arboreal fungus Trametes versicolor (17).
This compound is a branched heteroglucan compo-
sed of glucose (74.6 %), mannose (15.5 %), xylose
(4.8 %), galactose (2.5 %) and fructose (2.2 %) with
branches at β (1→3) and at β (1→6) connected with
a peptide fragment containing 18 amino acids (13).
Its molecular weight was estimated at 9-100 kDa.
Like the above-mentioned lentinan, krestin shows
a considerable antitumor activity against allogenic
and syngenic animal tumors (13). Its mechanism of
action consists in modification of host immune re-
sponse to tumor PSK increases lymphocyte activa-
tion and stimulates cytokine production by the cells.
Activation of NK and LAK (lymphocyte activated
killer) cells was confirmed in vivo and in vitro. This
substance was also proven to inhibit activity of me-
taloproteinases and other enzymes participating in
metastasizing of tumor cells (13), and to possess an-
tioxidant properties, so it can protect healthy tissues
during the combined therapy. Protein ñbound poly-
saccharide PSK exhibits marked antitumor effects
against allogenic tumors such as Sarcoma 180 and
Erlich carcinoma of experimental animals by both
intraperitoneal and oral administration (18). As it
has a protein fragment, it can be used orally. PSK is
also able to inhibit development of tumors induced
by various chemical and biological factors (viruses)
(18). This attractive bracket fungus is also known as
Coriolus versicolor. This species is very common
and widespread. It usually grows on hardwood logs
and stumps. 
Another polysaccharide with wider application
spectrum is schizophyllan, obtained from mycelial
cultures of the species Schizophyllum commune. It is
a branched β-glucan with β (1→3) bonds in skeletal
chain and β (1→6) in side chains. Experimental stu-
dies with this compound showed that it inhibited
Sarcoma-180 in mice (11). Further studies also indi-
cated that it was active against tumors of the lung,
digestive tract, breast and uterus. After removal of
primary tumor, it inhibited lung metastases in mice
with Lewis carcinoma. It was efficient in urinary
bladder cancer (in rats). Considering its relatively
wide spectrum of activities, it can be assumed that
its effects rely mostly upon activation of natural de-
fense of the body against pathological changes. It
was also noticed that the best results with these com-
pounds could be achieved when used in combination
with cytostatic drugs i.e., so-called immuno-chemo-
therapy (11). Schizophyllum commune is common,
grow whole year, gregarious on dead and living wo-
od of decidious trees, rarely on conifers.
Studies of polysaccharides isolated from fru-
iting bodies of higher fungi and from mycelial cul-
tures have demonstrated differences between secon-
dary metabolites. Polysaccharide KS-2, isolated
from Lentinus edodes mycelial cultures is a mannan
containing a peptide fragment. Laboratory tests de-
monstrated its ability to inhibit development of Ehr-
lich carcinoma and Sarcoma-180 in mice after intra-
peritoneal and oral administration. It also induced
interferon biosynthesis in experimental animals (14,
18).
Mycelial cultures of Agaricus blazei are the so-
urce of a number of polisaccharides possessing im-
munomodulatory properties, which include β-D
(1→6)-(1→3) glucan, β-D(1→6)-(1→4) glucan,
glucomannan complex ATOM and protein-mannan
complex (AB-FP). These fractions showed antitu-
mor activity against breast cancer and ovarian, and
hepatic carcinoma cells (19-21). The mushroom was
first identified to modern science in 1917 from
a specimen found in Louisiana by the mycologist R.
Murrill. It has been found on the grasslands of Flo-
rida and South Carolina, but it is generally thought
to be extremely rare in nature. The only place that it
has been found readily growing in nature is a small
area of Brazil.
The experiments have been carried out on such
species as Tylopilus felleus, Trametes gibbosa, Tra-
metes hirsuta, Inonotus bliquus (22-26). A polysac-
charide isolated from Tylopilus felleus named tylopi-
lan has a structure of homoglycan of β (1→3) type
with branches at β (1→6). In laboratory tests, it
exhibited antitumor activity against transplantable
Sarcoma-180 in mice (more than 98 % inhibition),
and destroyed glioma cells (23). It showed immuno-
modulatory properties, influencing non-specific cel-
lular immunity and some stages of specific humoral
response. It also showed mitostatic effect at a cellu-
lar level. At the same time it was found that tylopi-
156 KATARZYNA SU£KOWSKA-ZIAJA et al.
lan also evoked cytostatic effects in tests on animal
neoplasmatic cells HeLa and KB (24). These species
are very common and grow under pine or spruce on
acid soils.
Literature data provide information about poly-
saccharides exhibiting antitumor properties and on-
ly fragmentary characterized in terms of their che-
mical structure. The most interesting of them with
respect to antitumor potential are polysaccharide
fractions containing glucuronoglucans, xyloglucans,
mannoglucans and xylomannoglucans, isolated
from Ganoderma lucidum. They suppress develop-
ment of Sarcoma-180 in mice (27). Glucans with
a similar structure and activity were isolated from
mycelial cultures of this species.
Polysaccharides described above and other re-
presentatives of macromycetes are listed in Table 1.
Other metabolites of fungal origin possessing cy-
totoxic, antitumor and immunomodulating acti-
vities
Cytotoxic, antitumor and immunomodulating
activities of fungal extracts can usually be attributed
to the presence of polysaccharide compounds. Ho-
wever, recently a great deal of substances have been
obtained which are not polysaccharides, but which
have cytotoxic effect on tumor cell lines. Montadial
A (1) is one of such compounds. It is an example of
cytotoxic monoterpene isolated from Bondarzewia
montana (45). It is cytotoxic for lymphocytic leuke-
mia cells in mice. It showed similar activity against
human promyelocytic leukemia HL 60, which indi-
cated that in the future it might be used in the treat-
ment of this type of tumor.
Secondary metabolites isolated from Laetipo-
rus sulphureus var. miniatus are other examples of
antitumor compounds. Of them, egonol (2), deme-
thoxyegonol (3) and egonol glucoside (4) showed
weak cytotoxicity against Kato III cells (46). The
species Pyroformes demidoffi was a source of two
polyphenols, fomecin A and B. However, it was
experimentally demonstrated that only fomecin B
(5) was cytotoxic for HeLa, EMDCK and FL cells
(47). Semisynthetic sesquiterpenoid coriolin B ana-
log, diketocoriolin B (6), isolated from Coriolus
consors was demonstrated to block growth and de-
velopment of Yoshida sarcoma (48).
Sesquiterpene derivatives of hirsutane like
hypnophilin (7), pleurotellol (8) and pleurotellic
acid (9) isolated from Pleurotus hypnophilus are al-
Table 1. Antitumor polysaccharides from mushrooms
Species Active component References
Agaricus blazei hetero-glucan 19, 20, 21
Agrocybe cylindracea α-glucan 28
Amanita muscaria α-glucan 28, 29
Auricularia auricula β-glucan, glucuronoxylomannan 30
Cryptoporus volvatus β-glucan 31
Dictyophora indusiata β-glucan 32
Flamulina velutipes β-glucan 33
Ganoderma lucidum β-glucan, ganoderan 27
Grifola frondosa β-glucan 34
Hypsizigus marmoreus β-glucan 35
Lampteromycer japonicus mannan 36
Lentinus edodes β-glucan, lentinan 14, 15
Omphalia lapidescens β-glucan 38, 39
Pleurotus ostreatus β-glucan 40
Polyporus mylittae β-glucan 41
Schizophyllum commune β-glucan, krestin 11
Trametes gibbosa glucan 25
Trametes versicolor heteroglucan 17
Tricholoma giganteum heteroglucan 42
Tylopilus felleus β-glucan, tylopilan 22, 23, 24
Volvaria volvacea β-glucan 43
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Figure 2. Structure of antitumor substances ñ derivatives from macromycetes.
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so interesting since they are characterized by
a strong cytotoxic activity (49). Moreover, two next
hirsutane derivatives i.e., desoxyhypnophilin (10)
and 1-desoxyhyphnohilol, obtained by Lentinus cri-
nitus fermentation, had cytotoxic effect on mouse
fibroblastoma L929 (44). In addition, the genus Pa-
nus contains sesquiterpenes like naematolon (11)
and naematolina (12), whose cytotoxicity is con-
nected with the presence of α and β unsaturated ke-
tone groups (49).
Apart from antitumor activity of the compo-
unds originating in fungi, they can also influence
other aspects of immunity. Efficient antifungal me-
tabolites (merulidial, tremediol, tremetriol and α-bi-
sabolol) were obtained from the species Merulins
tremellosus, but only sesquiterpene ñ merulidial (13)
showed cytotoxic activity, suppressing DNA bio-
synthesis in ECA cells, and had also character of
a mutagen. The remaining above mentioned compo-
unds caused apoptosis of promyelocytes of human
leukemia HL 60 (50).
In the Far East, medicinal properties of fungal
extracts have been known for ages. Ganoderma lu-
cidum belongs to the fungi that have long been wi-
dely used in traditional medicine in such diseases
as tumors, hepatitis, asthma, hemorrhoids. Fruiting
bodies of this fungus and related Ganoderma ap-
planatum were used to isolate numerous triterpeno-
ids of lanostan type, such as lucidenic acid (51),
ganodermanodiol (14), ganodermanotriol (15) and
ganoderiol (16), which are strong activators of the
complement system that plays a significant role in
inducing humoral response in human body (52).
Furthermore, ganoderic B, ganolucidic A acids and
lucidumol B, isolated also from Ganoderma pfei-
ferri, were demonstrated to inhibit HIV protease
(53).
A great attention has been focused on secon-
dary metabolites isolated from mycelial cultures.
For instance, calvatic acid (antibiotic) was isola-
ted from Calvatia craniformis. It inhibits growth
and development of Yoshida sarcoma and mouse
leukemia L-1210 (54). Aranoflavins A and B,
which affected growth of Yoshida sarcoma, were
isolated from Arachniotus flavoluteus (55). Anti-
tumor antibiotic SL-1846 was isolated from in vi-
tro Pseudeurotium ovalis cultures. It was shown to
suppress proliferation of P-815 mastocytoma in
mice (56). Bredenin from Eupenicilium brefeldia-
num (micromycetes) is an example of imidazole
nucleoside, which blocks development of leuke-
mia (57).
Intensive search for new substances possessing
antitumor activity and examination of their biologi-
cal properties may pave the way for introduction of
new drugs into therapy. The described above exam-
ples authenticate the need of mycochemical rese-
arch, which can lead to isolation, identification and
defining biological activity of compounds that are
contained in different species of fungi.
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